CompletedNot Applicable

Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application

Germany95 participantsStarted 2021-08-01

Plain-language summary

In a retrospective observational study, critically ill COVID-19 patients admitted to the ICU with the CoV-2 delta-variant between august 2021 and february 2022 were evaluated (ethics application nr. 129/22 of the ethics commssion of the university Ulm.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Clinical diagnosis of COVID-19 * CoV-2 delta-variant * critically ill patients * ICU Exclusion Criteria: * tuberculosis * active hepatitis * HIV

What they're measuring

Mortality rates in the 4 groups

Timeframe: 28-day mortality

Trial details

NCT IDNCT06233357

SponsorUniversity of Ulm

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-04-28

View on ClinicalTrials.gov More COVID-19 trials